Clinical applications of infusion systems

Jc, Pickup

doi:10.3109/03091908409018186

Cited by 6 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous experience has shown that closed-loop BSL control using real-time continuous measure-ments of venous whole blood glucose level is viable and effective in glycaemic regulation [3][4][5] . Older systems however suffered many problems with the glucose sensor, limiting the length of treatment possible [6][7][8] . The portability of the older systems was also very limited 1,7 .…”

mentioning

confidence: 99%

Closed-loop Control of Blood Glucose Levels in Critically Ill Patients

Chee

Fernando

Heerden

2002

Anaesth Intensive Care

View full text Add to dashboard Cite

A closed-loop control system was constructed for automatic intravenous infusion of insulin to control blood sugar levels (BSL) in critically ill patients. We describe the development of the system. A total of nine subjects were recruited to clinically test the control system. In the patients who underwent closed-loop control of BSL, the controller managed to control only one patient's glycaemia without any manual intervention. The average BSL attained during closedloop control approached the target range of 6-10 mmol/l, and had less deviation than when BSL had been maintained manually. We conclude that closed-loop BSL control using a sliding scale algorithm is feasible. The main deficiency in the current system is unreliability of the subcutaneous glucose sensor when used in this setting. This deficiency mandates high vigilance during use of the system as it is being developed.

show abstract

mentioning

confidence: 99%

Closed-loop Control of Blood Glucose Levels in Critically Ill Patients

Chee

Fernando

Heerden

2002

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

“…Vem crescendo o interesse por formulações e vias de administração que promovam a localização/direcionamento de fármacos ao sítio alvo e contornem seus efeitos adversos sistêmicos, o que, na maioria das vezes, está associado à baixa adesão ao tratamento (52)(53)(54)(55). Além disso, a possibilidade de redução da frequência de dosagem é geralmente associada à melhoria da adesão aos tratamentos, principalmente crônicos.…”

Section: Liberação Sustentada E Sistemas De Liberação Líquidocristalinounclassified

Sistemas biorresponsivos para liberação sustentada de fármacos visando a quimioprevenção do câncer de mama.

Salata¹

View full text Add to dashboard Cite

Despite the high incidence of breast cancer, there are few pharmacological strategies for chemoprevention, and their serious adverse effects, result in low adherence. Retinoids are capable of inhibiting mammary tumors development due to regulation of cell growth and differentiation, and, among them, fenretinide is considered promising for breast cancer chemoprevention for its ability to accumulate in breast tissue. However, the drug presents serious adverse effects, and its high lipophilicity results in low oral bioavailability. To overcome these limitations and enable its use in chemoprevention, the present study aimed at developing bioresponsive microemulsions capable of uptaking in situ fluids after subcutaneous administration and transforming into a liquid crystalline phase that provides prolonged and local fenretinide release. Several microemulsions were prepared, and those composed of [phosphatidylcholine]:[monoolein:tricaprylin]-propylene glycol in the proportions 1:1-30% and 9:1-50% were selected. They presented diameters below 230 nm, originated liquid-crystalline phase when added 1% or more of water, and prolonged Alexa Fluor 647 release in vivo for more than 30 days; however, the microemulsion 1:1-30% caused local irritation and the formation of a fibrous capsule. Fenretinide was incorporated at a concentration of 1% (m/m), and its release followed pseudo-first order kinetics, Treatment of MCF-7 and T47D cells with the formulation 9:1-50% loaded with fenretinide was more cytotoxic compared to 1:1-30%, leading to its the selection for subsequent studies. Treatment with the fenretinide-loaded 9:1-50% formulation reduced cell migration by 65.2 and 75.9% when used in concentrations equivalent to IC5 and IC15 (concentrations required to reduce viability by 5 or 15%) compared to untreated cells, respectively. In 3D models, treatment with 9:1-50% at a concentration equivalent to IC30 reduced the viability of spheroids by 28.8% compared to the untreated control. In the animal model of chemically induced carcinogenesis, the 9:1-50% formulation was safe and effective, inhibiting the development of breast tumors.The promising results point to the potential of this formulation as new platform for chemoprevention of breast cancer.

show abstract

Biosensors: A Clinical Perspective J. C. Pickup

Pickup

1985

The Lancet

View full text Add to dashboard Cite

Clinical applications of infusion systems

Cited by 6 publications

References 65 publications

Closed-loop Control of Blood Glucose Levels in Critically Ill Patients

Closed-loop Control of Blood Glucose Levels in Critically Ill Patients

Sistemas biorresponsivos para liberação sustentada de fármacos visando a quimioprevenção do câncer de mama.

Biosensors: A Clinical Perspective J. C. Pickup

Contact Info

Product

Resources

About